A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...

At long last, the Food and Drug Administration's Center for Biologics Evaluation and Research Director Vinay Prasad is out.

Vaccine effectiveness was 38 to 41 percent against influenza outpatient visits, 41 percent against flu-linked hospitalization for children younger than 18 years ...

White House officials are trying to get him — and his Make America Healthy Again allies — to stop. Some Trump administration officials are eager to distance themselves from a topic they see as ...

FDA advisers recommend fall flu shot changes to include the new subclade K H3N2 variant for the 2026-27 season, improving vaccine relevance.

The US FDA’s vaccine advisors have recommended that three new influenza strains be included in next winter’s influenza vaccine, aiming in part to tamp down illness caused by subclade K, a mutated form ...

The US Food and Drug Administration (FDA) vaccine advisory committee has approved updated influenza vaccine strains for the upcoming flu season, while emphasizing the need for vaccines that offer ...

Although the Centers for Disease Control and Prevention (CDC) classifies the current flu season as “moderate,” at least 90 children have already died of influenza. Among the children who died and were ...

Vinay Prasad will leave FDA CBER by end of April, returning to UCSF after a one-year sabbatical, following a prior departure ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

The Food and Drug Administration's controversial vaccine chief, Dr. Vinay Prasad, is once again leaving the agency.